US FDA ends Alembic Pharma’s Vadodara unit inspection with one observation

The inspection, conducted from March 3-7, 2025, resulted in the issuance of a Form 483 with one procedural observation. Shares of Alembic Pharmaceuticals Ltd ended at ₹847.80, up by ₹36.70, or 4.52%, on the BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *